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a b s t r a c t
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and leading cause of cancer-
related deaths worldwide. In recent years, there has been a growing realisation that lifestyle plays a ma-
jor role for CRC development and that intestinal microbiota, which are shaped by lifestyle and nutrition
habits, may be critically involved in the pathogenesis of CRC. Although the precise mechanisms for how
the microbiota contribute to CRC development and progression remain elusive, increasing evidence sug-
gests a direct causative role for the intestinal microbiota in modulating signalling pathways, anti-tumour
immune responses and cell proliferation. Recent advances in understanding host-microbe interactions
have shed light onto the putative use of intestinal microbiota as a powerful tool in CRC diagnosis and
therapy. Here, we will discuss the role of the intestinal microbiota in CRC pathogenesis, their potential
utility as diagnostic markers, and consider how microbes could be used in therapeutic approaches for the
treatment of CRC.
© 2019 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
1. Introduction
Colorectal cancer (CRC) is the third most frequent cancer in
the Western world and the second leading cause of cancer-related
death worldwide. [1]. In recent years, despite improvements in
screening and treatment options and approaches [2], CRC is still
curable only in its early stages. This fact is demonstrated by the
age standardised 5-year survival rates that vary between 70% in
Korea to 60–69% in USA and Europe to less than 50% in Russia
and India. In particular, 5-year survival rates in patients with UICC
stage IV disease are still below 20% [3].
CRC aetiology has been linked to hereditary genetic syndromes,
family history of CRC, inﬂammatory bowel disease (IBD), and, par-
ticularly, environmental and lifestyle risk factors, such as obesity,
alcoholism, tobacco, and diet [4]. It is anticipated that the num-
ber of patients suffering from CRC will signiﬁcantly rise within
the next twenty years, associated with a rise in Western lifestyle
practices and diet, particularly as these Western inﬂuences become
more common also in Asia, Africa, and South America [5]. Clear as-
sociations have been demonstrated between the risk of developing
CRC and consumption of certain food types, such as red meat, and
nutrients, which act to either promote or reduce the risk of de-
∗ Corresponding author.
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veloping CRC [6]. Most of these environmental factors have been
associated with an effect on the indigenous intestinal microbiota,
causing a detrimental alteration known as dysbiosis [7]. Accord-
ingly, the intestinal microbiota or its derived metabolites may be
acting as the direct environmental modiﬁers for the risk to develop
CRC, given the known associations of dietary habits on systemic
immune responses, inﬂammation, intestinal immune responses to
bacteria, as well as intestinal microbiota composition and function-
ality overall. This profound effect of microbiota on determining im-
mune responses is exempliﬁed by observations from the use of an-
tibiotics in early childhood, which have been associated with in-
creased colonic adenoma formation in later life, the precursor le-
sion to CRC [8,9].
Given recent technological and technical advances, there have
been signiﬁcant strides forward in our understanding of the rel-
evance for intestinal microbiota in health and disease. In par-
ticular, through identiﬁcation of several microbial signatures as-
sociated with CRC and related pathologies such as IBD. Despite
these advances and the signiﬁcant potential for modulating intesti-
nal microbiota for the host beneﬁt as part of a future person-
alised/precision medicine approach, our knowledge about how mi-
crobiota may be used as a diagnostic tool or which bacterium or
mix of bacteria could treat or prevent CRC is still in its infancy. This
highlights the need to move away from spurious, often retrospec-
tively identiﬁed associations, greater scrutiny to prove causation
https://doi.org/10.1016/j.ebiom.2019.09.050
2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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and not just correlation, as well as highlighting the importance of
functional data to better understand the complex microbiota-host
interplay.
2. Intestinal microbiota composition and CRC
The human intestine is a highly populated microbial ecosys-
tem. The bacterial concentration increases from 107–8 cells per
gram of faecal content in the small intestine to >1011 in the colon
[10]. In healthy subjects, the gut is primarily populated by a core
microbiota composed of obligate anaerobes belonging mainly to
the phyla, Firmicutes and Bacteroidetes and to a lesser extent to
Actinobacteria, Proteobacteria, and Verrucomicrobia [11]. However,
speciﬁc insults to the gut may lead to disturbances in the com-
position of intestinal microbiota, a term named dysbiosis. Such in-
testinal dysbiosis is associated with a number of inﬂammatory dis-
eases along the gastrointestinal tract, including IBD [12,13], coeliac
disease [14,15], or lymphocytic gastritis [16]. However, it is unclear
whether dysbiosis occurs as a cause or consequence of inﬂamma-
tion, particularly, whether intestinal dysbiosis represents the result
of an inﬂammatory process or if, factors leading to inﬂammation
(diet, obesity, host genetics) are responsible for the development
of an altered microbial composition.
Nevertheless, the onset of CRC has been strongly associated
with intestinal dysbiosis and an altered composition of micro-
biota at the intestinal mucosal surface of the tumour as well as
the tumour-adjacent tissue [17–19]. Two recent meta-analyses of
faecal metagenomes revealed that on a functional level, bacte-
rial metagenomes associated with CRC have increased expression
of genes involved in protein, mucin and choline metabolism as
well as for gluconeogenesis and fermentation pathways, but re-
duced expression of genes associated with carbohydrate degra-
dation. Given such metagenomes have also been linked with en-
hanced secondary bile acid production, this may suggest an asso-
ciation between CRC-associated intestinal microbiota pattern and a
fat- and meat-rich nutrition [20,21].
3. Intestinal microbiota and CRC pathogenesis
There is increasing evidence to support that a number of bac-
teria, e.g. Fusobacterium nucleatum or Bacteroides fragilis are asso-
ciated with the onset of CRC in humans [22]. This effect may be
due to the intestinal microbiota themselves, the toxins the bacteria
may produce, and/or the metabolites formed as fermentation by-
products, all of which can profoundly inﬂuence intestinal home-
ostasis, leading to pro- or anti-inﬂammatory immune responses
and subsequent development of CRC [23]. The inﬂammatory state
that is driven by intestinal microbiota is thought to have an im-
pact on CRC development and progression [23]. Typically, CRC de-
velops in a stepwise process resulting in the accumulation of ge-
netic and epigenetic alterations. During this process there is a tran-
sition from normal to hyperproliferative epithelium, known as hy-
perplasia. When hyperplasia occurs, the intestinal epithelium loses
its characteristic architecture and functions, and becomes dysplas-
tic. Dysplasia can result in the development of non-malignant ade-
nomas, known as polyps, which eventually may invade the submu-
cosa and lead to a carcinoma. Microbiota have been demonstrated
to play a key role in this adenoma to carcinoma, tumour formation
and progression pathway [24,25].
More recently, the microbial formation of bioﬁlms has been
proposed as a driving factor in the early stage of CRC development.
Bioﬁlm formation allow bacteria to attach together and protect
themselves from the action of external agents. Expansion of bac-
teria within bioﬁlms negatively affects the intestinal epithelium
and reduces the levels of E-cadherin in colonic crypts. As a con-
sequence, intestinal permeability increases and the inﬂammatory
response driven by interleukin (IL)-6 and signal transducer and
activator of transcription (STAT) 3 is activated [26]. Of note, this
bioﬁlm formation is mainly associated with right-sided colon
adenomas and cancers, whilst bioﬁlm formation is infrequently
demonstrated in left-sided CRC [27]. Examination of bioﬁlms
attached to the colonic mucosa of patients with familial adenoma-
tous polyposis, has demonstrated a predominance of E. coli and B.
fragilis which may be contributing to the high risk for developing
CRC in those patients [28]. The importance of bioﬁlms has been
underlined, by ﬁndings supporting their oncogenic potential and
an ability to induce CRC in mice regardless of whether they are
derived from tumour tissue or healthy human colonic tissue [29].
In CRC patients, the impairment of the intestinal epithelium,
and resulting intestinal barrier dysfunction, facilitates the translo-
cation of microbes from the lumen to the lamina propria and
the induction of cytokines, including IL-17 and IL-23, which act
to maintain the inﬂammatory microenvironment within the tu-
mour [30]. In a study using IL-10 knockout mice, modiﬁcation of
intestinal microbiota driven by intestinal inﬂammation, promoted
the expansion of genotoxic bacteria resulting in tumour formation
[31]. Interestingly, obesity, which is characterised by systemic low-
level inﬂammation and intestinal dysbiosis, has also been linked
to an increased risk for CRC development. This increased risk in
obese patients may be due to observed associations including a
decreased proportion of Bacteriodetes in the intestine [32], and
the overall bacterial richness being lower compared to lean peo-
ple [33].
Another prominent cause of CRC is colitis-associated cancer
(CAC). CAC develops from long-standing colitis in patients with IBD
and greater risk for CAC has clearly been associated with greater
inﬂammatory burden over time. Patients suffering from IBD have
a reported increase in their risk of CRC development by up to
20% after 30 years [34]. The increased incidence of CRC in IBD pa-
tients may depend on several factors, including extent and sever-
ity of intestinal inﬂammation, disease severity, duration of disease,
treatment as well as management and surveillance strategies [35].
Similar to CRC, dysbiosis of the intestinal microbiota has been re-
ported to play an essential role in IBD pathogenesis [12]. E. coli
NC101 mono-colonization studies have further supported the link
between inﬂammation and CRC onset. In this instance, the intesti-
nal inﬂammation in IL-10 deﬁcient mice has been demonstrated to
promote a speciﬁc phenotype of intestinal dysbiosis and the sub-
sequent mono-colonization with this E. coli strain enhanced colon
tumourigenesis in vivo [31].
There is also increased evidence for an important role of F. nu-
cleatum in CRC pathogenesis. The presence of the gram-negative
anaerobic bacterium F. nucleatum in CRC tissue has been inversely
correlated with the number of CD3+ T-cells in CRC tissue suggest-
ing a possible involvement of this bacterium in the regulation of
anti-tumour immune responses [36]. On a functional level, F. nu-
cleatum is able to inhibit the activity of natural killer (NK) cells
targeting cancer cells via binding of the bacteria-derived protein
Fap2 on exclusively human T cell immunoglobulin and ITIM do-
main (TIGIT) molecule [37], suggesting that F. nucleatum is involved
in regulating tumour immune-evasion processes, which are critical
for the development and progression of CRC. However, F. nuclea-
tum does not only seem to be involved in CRC pathogenesis, but
also in modulating response to CRC therapy. Particularly, F. nuclea-
tum is able to induce the activation of autophagy machinery, in
an effect mediated by targeting of speciﬁc microRNAs. Addition-
ally, F. nucleatum also interferes with the activation of the TLR4
pathway. The end-point of these mechanisms, results in promotion
of chemoresistance of CRC cells in vivo [38]. Accordingly, F. nuclea-
tum has been more frequently detected in cancerous tissue from
patients with recurrent tumours and is associated with worse sur-
vival rates of CRC patients. As well as in recurrent tumours, F. nu-
650 A. Montalban-Arques and M. Scharl / EBioMedicine 48 (2019) 648–655
cleatum has been found in tissue derived from CRC metastases. The
potential of microbial modulation has been demonstrated from the
use of antibiotic treatment targeting F. nucleatum, which is eﬃcient
to reduce not only bacterial load, but also tumour cell growth and
proliferation in human CRC xenograft models [39]. Supplementa-
tion of diet with foods rich in ﬁbre has also been associated with
lower risk for F. nucleatum –positive CRC, again supporting a poten-
tial role of the microbiota as mediator between diet and CRC [40].
Aside from gut bacteria themselves, bacteria-derived virulence
factors may also be involved in the promotion and development of
CRC. F. nucleatum secretes an anchoring adhesion molecule named
FadA. The link between FadA and E-cadherin on intestinal epithe-
lial cells results in an impairment of the paracellular adhesions, al-
lowing the penetration of pathogens to the submucosa. This drives
a consequent inﬂammatory response and activates β-catenin sig-
naling to further enhance the activity of pro-oncogenic pathways
[41-43]. B. fragilis is another gut microbe that has been shown to
be enriched when analysing microbial composition from the in-
testine of patients with CRC. B. fragilis subgroup ETBF produces
the toxin fragylisin, which is a metalloproteinase that cleaves E-
cadherin on colonocytes. Fragylisin increases mucosal permeabil-
ity, enhances IL-17 cytokine secretion as well as STAT3 activa-
tion, and is increased in patients with advanced CRC [44]. A re-
cent elegant approach used a speciﬁc bacterial enzyme expressed
by intratumoural bacteria, speciﬁcally the long isoform of bacte-
rial cytidine deaminase, to demonstrate a contribution to gemc-
itabine resistance via degradation of this chemotherapeutic agent
in CRC tumours. Of interest, this enzyme is expressed e.g. by Kleb-
siella pneumonia or E. coli strain K-12 and the authors were able
to demonstrate that antibiotic treatment eradicating those bacteria
enhanced the eﬃcacy of gemcitabine in mouse CRC models in vivo
[45].
Reactive oxygen species (ROS) and reactive nitrogen species
(RNS) induce inﬂammation and DNA damage. Oxidative stress
causes DNA mutations, dysplasia, and thus facilitates tumour de-
velopment [46]. Although ROS are generated by macrophages and
neutrophils during inﬂammatory processes, they can be produced
as well by certain microbiota species including Enterococcus faecalis
[47]. These ﬁndings strongly support the idea that particular mi-
crobes, which are enriched in an inﬂammatory microenvironment,
contribute or even cause the onset of CRC. A summary of microor-
ganism that have been linked to CRC development, their associated
virulence factors, and proposed pathogenic mechanisms are high-
lighted in Table 1.
4. Microbiota as diagnostic markers
As demonstrated, the causative relationship between the in-
testinal microbiota and CRC development is complex. Identiﬁca-
tion of candidates in a one microorganism-one disease model
is challenging, highlighted by the diﬃculty in dissociating effect
and cause. However, notable progress in the ﬁeld has been made
through identiﬁcation of microbial signatures associated with and
speciﬁc to patients with CRC. Flemer et al., found an increased
abundance of Bacteroides, Roseburia, Ruminococus, and Oscilobacter
in mucosal samples from patients with CRC (n=70) compared to
healthy controls (n=56). Moreover, the authors observed regional
differences between distal and rectal versus proximal cancers from
the same mucosal samples [48]. A decrease in Firmicutes and Bac-
teroidetes, the most prominent phyla in healthy individuals and
lactic acid bacteria have also been associated with CRC [25,49].
Even accounting for the differences in microbial composition from
different stages of disease and treatment, there is still signiﬁcant
inter-individual heterogeneity, with no single OTU being identiﬁed
as causative in all individuals with CRC. This is perhaps unsurpris-
ing given the increasing evidence of molecular subtypes of CRC and
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different pathogenic mechanisms driving each individual subtype
[50]. Instead, co-abundance groups (CAGs) of organisms determin-
ing the community structure are more informative and could be
used in the early detection of CRC [48,51].
In a multi-cohort study including Chinese, Austrian, American,
German, and French patients, meta-analysis of shotgun metage-
nomics on CRC identiﬁed a group of bacteria consistently en-
riched in CRC across multiple populations. In addition to dif-
ferences in bacterial composition, some bacterial pathways were
positively correlated with CRC, such as Lipopolysaccharide (LPS)-
related pathway, biosynthetic pathways, or pathways being rele-
vant for metabolism of cofactors and vitamins [52]. In a further
metagenome-wide association study involving Chinese and Danish
patients with CRC, the authors identiﬁed two new species associ-
ated with CRC, Parvimonas micra and Solobacterium moorei. The au-
thors also discovered 20 gene markers signiﬁcantly associated with
CRC microbiomes in the Chinese cohort. From those, four were
validated in the Danish cohort and later in external French and
Austrian cohorts [53]. Given these promising ﬁndings, stool mi-
crobiota have been further investigated as a putative non-invasive
biomarker for CRC detection [17,54].
In a cohort of 170 CRC patients and 200 healthy control subjects
the presence of F. nucleatum in faecal samples from cancer patients
was identiﬁed as a potential biomarker for the onset of CRC. Pres-
ence of only F. nucleatum demonstrated high sensitivity and speci-
ﬁcity of about 80%. The combination of four bacteria in the fae-
ces, F. nucleatum (Fn), Bacteroides clarus (Bc), Clostridium hathewayi
(Ch) and one undeﬁned species (m7), improved these values only
to a small extent. However, the combination of those four bacteria
with the result of the faecal immunochemical test (FIT) increased
the sensitivity to detect CRC up to 92.8% and even up to 100% in
stage II CRC. Such an approach offers signiﬁcant promise for incor-
poration into routine clinical practice to aid diagnosis. In addition
to diagnosis, levels of F. nucleatum within the CRC tumour tissue
have also been associated with poorer clinical outcomes and prog-
nosis [55]. Whilst this prognostic element would need further in-
vestigation and validation, the clinical utility of such a biomarker
would be even further enhanced if both predictive and prognostic
capability were to be demonstrated.
In recent years, extracellular bacterial peptides encrypted in the
intestinal exoproteome have been proposed to possess bioactiv-
ity and immunomodulatory capacity to maintain the mucosal bar-
rier [56–58]. Beyond these roles, the potential for bacterial pep-
tides to be used as biomarkers of gut homeostasis have also been
reported. IgA serum levels elevated in response to certain bac-
terial peptides have been proposed as a diagnostic biomarker to
help discriminate patients with IBD from healthy controls. In the
same study, the authors demonstrated that IgA serum levels dis-
tinguished between patients with CD and those with UC, in both
the active or quiescent disease. Analysis of the bacterial peptides
in thus study showed capacity to modulate the intestinal cytokine
milieu on resting conditions and in the presence of LPS [59]. Bacte-
rial peptides may offer signiﬁcant promise as potential biomarkers
not only in IBD, but also as a promising tool for the development,
diagnosis, and progression of CRC.
Despite the wide-ranging studies which have identiﬁed associ-
ations and potential for microbiota to be used in diagnosis of CRC,
there remains a lack of consensus on many fronts. The discordant
ﬁndings from these studies may be due to differences in the col-
lection, storage, and processing of faecal samples, DNA extraction,
ampliﬁcation, as well as the bioinformaticworkﬂow consisting of
sequencing, normalization of data, and subsequent bioinformatic-
analyses [60]. Despite these limitations, microbial markers are a
promising tool in the detection of CRC. Future research should fo-
cus on the detection of early stages of CRC, such as polyps, adeno-
mas and other related CRC (pre-)lesions, which have been a limi-
tation of microbial markers to date, as most studies have focused
on detection for more advanced stages of the disease [61,62].
5. Microbiota as therapeutic approach in CRC
The intestinal microbiota is characterised by temporal stability
and a pronounced capacity for resilience. However, acute pertur-
bations initiated from either the host or the microbial side may
require prolonged periods for the microbiota to recover. This per-
turbation and resulting microbial dysbiosis can elicit permanent
changes locally or in other tissues, that may lead to chronic dis-
eases such as IBD [63] The establishment of native microbiota and
the interplay with the host immune system is crucial for the devel-
opment during childhood. It has been recently reported that early-
life antibiotic exposure, caesarean section, and formula feeding can
lead to an immature microbiota, having adverse consequences later
in life, including increased risk of obesity, diabetes, IBD, asthma,
and various allergic or hypersensitivity reactions [64]. Therefore,
the ultimate and elusive goal in cancer therapy remains the dis-
covery of bacterial species or a combination of them that either
prevent the onset of CRC, promote anti-tumour responses or en-
hance the eﬃcacy of existing medications.
In recent years, diverse studies have shown the possibility of
applying dietary strategies to modulate the intestinal microbiota.
The aim of such work is to encourage the growth of certain bacte-
rial strains that may convert indigestible dietary components into a
large variety of metabolites with beneﬁcial effects for the host [65].
It is now well recognised that “Western” diets rich in animal fats
and red meat, while poor in fruit and vegetable intake predispose
to inﬂammatory and metabolic diseases, as well as CRC [66–68].
Dietary ﬁbre has been identiﬁed as an important source of bene-
ﬁcial bacterial metabolites i.e. short-chain fatty acids (SCFAs). Di-
etary ﬁbre is resistant to digestion and absorption in the small in-
testine, but speciﬁc members of the resident intestinal microbiota
can ferment these polysaccharides, including resistant starch, cellu-
lose, pectins, oligosaccharides, and lignins, either partially or com-
pletely [69]. Compelling evidence for the impact of diet on risk of
developing CRC was provided by a study where a native African
cohort who have generally a low CRC rate, and African-American
cohort switched their diets for 2 weeks. The dietary changes from
traditional high-ﬁbre diet to Western diets and vice versa resulted
in rapid and reciprocal changes in the microbiome, affecting the
levels of SCFAs, including butyrate, and the mucosal biomarkers
of CRC risk [70]. The importance of dietary ﬁbre has also been
demonstrated in a meta-analysis where CRC risk could be reduced
by 10% per additional 10 g/day of total dietary ﬁbre intake [71].
With rapidly expanding understanding of pre- and probiotics, it
is increasingly likely that bioactive food components and certain
members of the microbiota could offer hope for therapeutic use
for the prevention and treatment of CRC.
In addition to its association with CRC development, intestinal
microbiota also have local and systemic effect in modulating the
eﬃcacy and toxicity of cancer therapy [72]. The ﬁrst important
ﬁndings on response to cancer therapeutics, were observed when
intestinal microbiota were found to control the response to cancer
chemotherapy by regulating myeloid-derived cell functions within
the tumour microenvironment. In this study, the authors showed
that LPS is essential to prime myeloid cells via TLR4 [73]. A fur-
ther study underlying the importance of microbial composition for
treatment response, studied the pro-carcinogenic phenotype ex-
pressed by some genetically mutated mice when stool transfer to
wild-type mice was performed by faecal microbiota transplantation
(FMT). In a similar way, FMT from patients responding to cancer
therapy to germ-free mice endowed those mice with the ability to
respond to the therapy [74]. Whilst the direct and indirect biolog-
ical mechanisms need to be determined, these data support that
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intestinal microbiota composition affect the eﬃcacy of anti-cancer
therapies.
In efforts to discover the underlying biology of host-microbial
interactions, a consortium of 11 bacteria in the stool of healthy
individuals were able to consistently induce the number of
IFNγ +CD8+ cytotoxic T-cells in the intestine of germ-free mice.
Notably, those 11 bacteria induced CD8+ T-cells without addition-
ally enhancing intestinal or systemic inﬂammation. The effect of
those 11 bacteria, appears to be mediated via a CD103+ den-
dritic cell- and major histocompatibility (MHC) class Ia molecule-
dependent pathway. On a functional level, the colonization of
mice undergoing a subcutaneous CRC mouse model with those
11-bacteria resulted in enhanced eﬃcacy of checkpoint inhibitor
treatment for CRC therapy [75]. Whilst these initial ﬁndings offer
promising signals, clearly further studies are needed to translate
microbiota-based therapies into clinical practice.
The most well recognised probiotics nowadays are those from
the genera Lactobacillus and Biﬁdobacterium. In a randomised con-
trolled trial, oral supplementation of lyophilised live L. acidophilus
and B. biﬁdum was shown to prevent intestinal toxicity in can-
cer patients treated with both radiotherapy and cisplatin [76].
These clinical data support the use of probiotic bacteria such as
L. acidophilus to promote an anti-tumour effect while preventing
the toxicity of the drug. Interestingly, two recent studies have
shown the inﬂuence of intestinal microbiota on the eﬃcacy of
anticancer therapy with immune checkpoint inhibitors. The anti-
cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) causes ep-
ithelial barrier disruption, allowing the penetration of bacteria into
the lamina propria and an alteration in the composition of in-
testinal microbiota. In a mouse model of subcutaneous melanoma
tumours, which poorly respond to anti-CTLA4 therapy, the rela-
tive abundance of Bacteroidales and Burkholderiales decreased in
favour of Clostridiales. Restoring B. thetaiotaomicron and B. frag-
ilis in microbiota-depleted mice enhanced the eﬃcacy of the anti-
CTLA4 therapy, by inducing the maturation of dendritic cells within
the tumours and TH1 response in tumour-draining lymph nodes.
The authors concluded that anti-CTLA4 therapy promoted not only
antitumour, but also anticommensal immunity, which served as
adjuvant for the anticancer therapy [74].
Unlike anti-CTLA4, programmed cell death protein ligand 1 (PD-
L1) blockade does not affect the intestinal barrier. However, Sivan
and colleagues demonstrated that intestinal microbiota plays again
a role in the eﬃcacy of the PD-L1 immune checkpoint inhibitor
blockade. The authors showed that mice from different vendors de-
veloped subcutaneous tumours at a different rate, which correlated
to a higher inﬁltration of CD8+ T cells in tumour tissue and lower
progression of tumours. When analysing the intestinal microbiota
they found that response to anti-PD-L1 therapy correlated with
higher relative abundance of Biﬁdobacterium species. This suggests
that anti-PD-L1 therapy against PD-L1-PD1 interaction is enhanced
by the presence of the certain probiotic, such as Biﬁdobacterium
spp [77]. Although these two studies were conducted in melanoma
models, immunotherapy is increasingly being used for the treat-
ment of other cancers, including CRC. The different strategies that
could be followed for CRC treatment using intestinal microbiota-
based approaches are summarised in Fig. 1.
Fig. 1. Potential microbiota therapies to treat CRC. Diet plays an important role in establishing the composition of intestinal microbiota. While a ﬁbre-rich diet will lead to
an anti-inﬂammatory-like microbiota, predominant in SCFAs producing bacteria, a western diet rich in animal fats and read meat, will lead to a pro-inﬂammatory microen-
vironment that may predispose to CRC. Several studies have demonstrated the role of microbiota in response to cancer therapy: (A) L. acidophilus and B. biﬁdum are able
to prevent intestinal toxicity in CRC patients treated with both radiotherapy and cisplatin [70]. (B) CTLA4 causes epithelial disruption and the consequent penetration of
bacteria into the lamina propria. However, this a priori adverse effect allows B. thetaiotaomicron and B. fragilis to enhance the eﬃcacy of anti-CTLA4 therapy by inducing the
maturation of dendritic cells within the tumours (C) [68]. (D) Biﬁdobacterium spp enhaces anti-PDL1 therapy [71]. (E) A deﬁned commensal consortium of 11 bacteria has
been shown to induce IFNγ +CD8+ T cells without enhancing intestinal inﬂammation in a CD103+ dendritic cell and MHC-I - dependent manner [69].
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6. Summary
The intestinal microbiome has been demonstrated to be criti-
cally involved in the pathogenesis of CRC. A broad number of high
quality studies have demonstrated the importance of intestinal mi-
crobiota, and accordingly diet, life-style and nutrition as its mod-
ifying factors, for the development of the disease. In addition to
a large number of studies demonstrating an association between
speciﬁc bacteria and CRC onset, a wealth of functional data exist
that reliably demonstrate the involvement of bacteria in pathways
and molecular mechanisms that culminate in the onset of CRC.
There have been promising initial ﬁndings for the use of intesti-
nal microbiota as predictive and/or prognostic markers for CRC. In
terms of translational potential, there is signiﬁcant optimise for
modulation of intestinal microbiota as a potential tool for treat-
ing CRC. In order to develop on these promising advances to date,
a greater understanding of the complex interplay between the in-
testinal microbiota and the onset of CRC is critical to utilize the
intestinal microbiota for the treatment of CRC.
7. Outstanding questions
The major limiting factor for translation of microbiota to iden-
tify therapeutic targets or even to be used as therapeutic agents,
is the fact that most of our knowledge about intestinal microbiota
and disease pathogenesis relies on associations, usually retrospec-
tively identiﬁed, and, often derived from animal models. However,
to use the intestinal microbiota or microbiota-based products in
complex disease areas such as oncology where there is the addi-
tional complexity of multiple therapeutic agents, we need to obtain
a greater understanding on the functional role of microbiota, par-
ticularly with respect to its immunologic, metabolic and cell phys-
iologic consequences in the human host. Obtaining such a criti-
cal understanding of the functional relationship between the in-
testinal microbiota and host physiology would enable us to de-
sign and deliver personalised/precision medicine approaches. The
aim of such an approach would be to allow speciﬁc modulation
of the intestinal microbiome for any one individual and to deliver
microbiota-based products, which can be used to directly treat dis-
ease for that individual. One could envisage, that such an approach
could be used to enhance the eﬃcacy of existing therapies or to
reduce the extent of side effects. The ultimate aim of a precision
oncology approach should be to promote development of nutri-
tional therapies, composed to foster of speciﬁc functional groups
of bacteria, which are able to act via the intestine to exert beneﬁ-
cial effects on human health and disease. Whilst such a vision may
currently seem futuristic. Given rapid advances in technology and
bioinformatic approaches, greater understanding about the func-
tional role of microbiota, as well as large prospectively studied and
well-phenotyped cohorts, we anticipate the potential use of micro-
biota modulation in the near future and look forward to the use of
such an approach to help deliver the goal of precision medicine for
patients with colorectal cancer.
8. Search strategy and selection criteria
Data for this Review were identiﬁed by searches of MEDLINE,
Current Contents, PubMed, and references from relevant articles
using the search terms “microbiota”, “colorectal carcinoma”, and
“colon cancer”. Abstracts and reports from meetings were included
only when they related directly to previously published work. Only
articles published in English between 1980 and 2019 were in-
cluded.
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